Project Grant R21AI193314
Award Date 7/20/26
Completion Date 6/30/28
Dollars Obligated $236K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $433,125 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to examine the subcellular proteome in response to influenza infection. The recipient will characterize and optimize AAV vectors for transduction of human precision cut lung slices (PCLS), test the localization efficiency of targeted MICROID2 constructs (a promiscuous biotin-ligase for measuring...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $787,498 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how intrinsic STING signaling shapes phagocytosis-dependent innate immunity. The research clarifies mechanisms by which STING (Stimulator of Interferon Genes) signaling, a cytosolic DNA-mediated innate immune response pathway, renders microbial-infected cells and DNA-damaged cells...
- The National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded The Ohio State University $354,416 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into novel peroxisome functions in Histoplasma capsulatum pathogenesis. The research will define the peroxisome proteome and metabolome in pathogenic-phase fungal cells to uncover new peroxisomal roles beyond known functions...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $3.1 million on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate CD8 T cell mechanisms of influenza virus clearance and pathology in cardiac tissue. The research addresses viral myocarditis, detected in up to 40 percent of hospitalized influenza patients and linked to higher risk of heart failure and death. Using a newly developed heart-tropic,...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $670,881 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how Anaplasma phagocytophilum, the causative agent of human granulocytic anaplasmosis, exploits host cell endoplasmic reticulum-Golgi transport machinery to facilitate infection. The research focuses on a bacterial Type IV secretion system effector protein called EGEA (endoplasmic...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Ohio State University a Project Grant of $433,125 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct basic research on influenza A virus (IAV) pathogenesis and acute respiratory distress syndrome (ARDS) mechanisms. The two-year research initiative, awarded July 2, 2025, and extending through June 30, 2027, investigates how the viral PB1-F2 protein...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Cincinnati Children's Hospital Medical Center (doing business as Children's Home Healthcare) a project grant of $486,000 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into riboregulation of innate immune signaling, specifically the role of RNA in organizing and regulating multiprotein signaling complexes called signalosomes. The research will...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $790,507 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of simian arterivirus entry, immune evasion, and zoonotic potential. The recipient will conduct molecular, biochemical, structural, and functional investigations of simian arteriviruses (SAVs)—understudied pathogens of African monkeys—to establish their capacity for human...
- The National Institute of Allergy and Infectious Diseases awarded the Trustees of Indiana University $658,213 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how chronic viral infections suppress dendritic cell function and impair secondary immune responses. The research examines mechanisms by which persistent viral infections such as HIV and hepatitis B and C alter CD8 T cell priming through decreased dendritic cell activation. The...
- The National Institute of Allergy and Infectious Diseases awarded The Ohio State University $692,930 on June 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on mechanistic regulation of HLA binding receptors during human natural killer cell development. The research examines how killer immunoglobulin-like receptors (KIRs) are expressed and regulated during natural killer (NK) cell development. NK cells serve critical immune functions...